NCT00118248View on ClinicalTrials.gov

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

August 31, 2009

Study Completion Date

April 30, 2012

Conditions
Recurrent Thyroid CancerStage IV Follicular Thyroid CancerStage IV Papillary Thyroid CancerThyroid Gland Medullary Carcinoma
Interventions
DRUG

tanespimycin

Given IV

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00118248 - Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | Biotech Hunter | Biotech Hunter